RISOLNET • KNOWLEDGE ENGINE
SCIENCE & TECHNOLOGY NEWS REVIEW
October 4, 2026
Science, space, artificial intelligence, technology and biotechnology
Today we move from the hidden far-infrared Universe to AI safety, semiconductor architecture, RNA cancer diagnostics and the expansion of CAR-T therapy beyond oncology.
01 • SPACE & ASTRONOMY
PRIMA: NASA’s New Window on the Hidden Infrared Universe
NASA has advanced PRIMA, the PRobe far-Infrared Mission for Astrophysics, into Phase B. It is the first project in the agency’s new Probe Explorers class. If it passes its future confirmation review, PRIMA is targeted for launch in 2033, with a project cost cap of $1.2 billion and a planned five-year mission.
Its roughly 1.8-metre cryogenic telescope will explore the far-infrared, filling an important observational gap between facilities such as the James Webb Space Telescope and radio observatories. Its science targets include protoplanetary disks, star formation, cosmic dust, black-hole growth and the origin of water in planetary systems.
Analysis
PRIMA is important not because astronomy needs simply another space telescope, but because different wavelengths expose different physics. Far-infrared observations can reveal cold material and dusty regions that are difficult or impossible to study in visible light.
The mission should therefore complement Webb rather than replace it. An important limitation remains: PRIMA has entered Phase B but has not yet received final confirmation for implementation and launch.
02 • ARTIFICIAL INTELLIGENCE
Another OpenAI Safety Researcher Leaves, Warning About the Pace of Development
Former OpenAI safety employee David Robinson has left the company and publicly criticised what he describes as a development culture moving too quickly relative to the ability to understand and control increasingly capable AI systems.
The debate comes as the AI industry moves from conversational systems toward persistent autonomous agents capable of using tools and pursuing goals over longer periods. OpenAI itself recently introduced dots, its new class of always-on agents.
Analysis
Robinson’s claims are the position of a former employee and should not be treated as proof that current systems are inevitably unsafe. The underlying engineering problem, however, is real: increasing autonomy increases the number of actions and system states that can occur without direct human intervention.
AI safety is therefore becoming less about whether a model produces one incorrect answer and more about what chain of actions that incorrect answer might initiate.
Sources:
Reuters |
OpenAI — Introducing dots
03 • TECHNOLOGY & COMPUTING
Huawei Mate 90: Working Around Chip Constraints Through Architecture
Huawei has unveiled its Mate 90 smartphone family, running HarmonyOS 7 and using the new Kirin 9050 Pro. One of the technically interesting elements is an architecture known as LogicFolding, designed to improve density and performance while China continues to face restricted access to the most advanced semiconductor manufacturing technologies.
Huawei says the Mate 90 Pro Max delivers a 31% performance improvement over its predecessor, while also acknowledging that advanced semiconductor manufacturing capacity in China remains constrained.
Analysis
When manufacturing-process improvements become difficult, engineers can recover performance through architecture, packaging, interconnects, software and system-level optimisation.
This does not eliminate the disadvantages of less advanced lithography, including potential trade-offs in yield, power consumption and manufacturing cost. It does show why semiconductor competitiveness can no longer be reduced to a single nanometre number.
Source:
Reuters
04 • BIOTECHNOLOGY & DIAGNOSTICS
A Urine Test Could Reveal Not Only Whether a Tumour Is Present, but What It Is Doing
Researchers at Stanford Medicine and the VA Palo Alto Health Care System have developed uRARE-seq, a test that analyses RNA fragments shed by tumour cells into urine.
In a study involving 683 urine samples, the assay identified 95% of people with localised bladder cancer and correctly classified 90% of people without the disease. It also detected residual disease and generated biological information associated with treatment response.
Analysis
The distinction between DNA and RNA is central. DNA can reveal which mutations are present; RNA provides information about which genes are actively being expressed. The test can therefore potentially provide a molecular snapshot of tumour behaviour rather than merely detect its genetic identity.
This remains clinical research rather than a routine replacement for cystoscopy. The researchers plan larger prospective multicentre validation studies before clinical adoption.
Source:
Stanford Medicine
05 • CELL THERAPY
CAR-T Therapy Is Moving Beyond Cancer
A new review in Signal Transduction and Targeted Therapy examines the rapidly expanding use of chimeric antigen receptor T-cell therapies in non-oncological diseases. CAR-T technology, developed primarily for haematological cancers, is increasingly being investigated for autoimmune and other diseases in which specific cell populations drive pathology.
Analysis
CAR-T therapy effectively turns immune cells into programmable biological devices: T cells are engineered with receptors that recognise a selected cellular target and trigger its elimination.
In cancer the target may be a malignant cell. In autoimmune disease, the same principle could be used to eliminate B-cell populations responsible for pathological autoantibodies. This transforms CAR-T from an exclusively anticancer strategy into a broader immune-engineering platform.
Manufacturing complexity, toxicity, cost and control of immune responses remain substantial barriers. A review of the field also does not establish clinical efficacy across all proposed indications.
THE SIGNAL
Today’s connecting idea is programmability.
PRIMA changes what part of the electromagnetic spectrum we can interrogate. Huawei redesigns architecture to work around manufacturing constraints. uRARE-seq reads the active molecular programme of a tumour. CAR-T rewrites immune-cell behaviour. AI agents transform software that answers into software that acts.
Technology is increasingly moving from building one specialised machine toward building systems that can be reprogrammed for new tasks. That flexibility is enormously powerful. It also gives us unprecedented opportunities to programme things incorrectly with remarkable efficiency.